Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Cisplatin
  • Glioblastoma
  • Hearing Loss
  • Radiation-Sensitizing Agents
  • Radiotherapy, Adjuvant

abstract

  • Increased exposure to CDDP increases the risk of ototoxicity over time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.

publication date

  • May 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s11060-005-9049-1

PubMed ID

  • 16273313

Additional Document Info

start page

  • 315

end page

  • 20

volume

  • 77

number

  • 3